uPA is upregulated by high dose celecoxib in women at increased risk of developing breast cancer

BMC Cancer

Volumn 8, Issue , 2008, Pages

  Qin, Wenyi ^a   Zhu, Weizhu ^a   Hewett, John E ^b   Rottinghaus, George ^b   Chen, Yin Chieh ^b   Flynn, John T ^c   Kliethermes, Beth ^a   Mannello, Ferdinando ^d,e   Sauter, Edward R ^a  

^a UNIVERSITY OF NORTH DAKOTA SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^b UNIVERSITY OF MISSOURI   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

^d THOMAS JEFFERSON UNIVERSITY   (United States)

^e UNIVERSITY OF URBINO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROSTAGLANDIN E2; UROKINASE; PYRAZOLE DERIVATIVE; SULFONAMIDE;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; BREAST CANCER; CANCER RISK; COUGHING; DIARRHEA; DOSE RESPONSE; DOWN REGULATION; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG ERUPTION; DRUG MEGADOSE; DRUG WITHDRAWAL; EDEMA; FEMALE; HEART PALPITATION; HUMAN; LOW DRUG DOSE; MUSCLE TONE; NAUSEA; NIPPLE ASPIRATION; POSTMENOPAUSE; PREMENOPAUSE; PROTEIN EXPRESSION; SIDE EFFECT; SWEATING; TASTE DISORDER; UPREGULATION; URINARY URGENCY; BLOOD; BREAST; BREAST TUMOR; CHEMISTRY; CLINICAL TRIAL; METABOLISM; MIDDLE AGED; NIPPLE; RISK FACTOR;

ADULT; AGED; AGED, 80 AND OVER; BREAST; BREAST NEOPLASMS; DINOPROSTONE; FEMALE; HUMANS; MIDDLE AGED; NIPPLES; PLASMINOGEN ACTIVATOR INHIBITOR 1; POSTMENOPAUSE; PYRAZOLES; RISK FACTORS; SULFONAMIDES; UP-REGULATION; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 56049119850     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-8-298     Document Type: Article

References (24)

1. Vassalli JD Baccino D Belin D A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase J Cell Biol 1985, 100(1):86-92 2113459 3880760 10.1083/jcb.100.1.86
2. Ellis V Behrendt N Dano K Plasminogen activation by receptor-bound urokinase. A kinetic study with both cell-associated and isolated receptor J Biol Chem 1991, 266(19):12752-12758 1829461
3. Duffy MJ Urokinase plasminogen activator and its inhibitor, PAI-1, as prognostic markers in breast cancer: From pilot to level 1 evidence studies Clinical chemistry 2002, 48(8):1194-1197 12142372
4. Andreasen PA Kjoller L Christensen L Duffy MJ The urokinase-type plasminogen activator system in cancer metastasis: A review Int J Cancer 1997, 72(1):1-22 10.1002/ (SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z 9212216
5. Ma Z Webb DJ Jo M Gonias SL Endogenously produced urokinase-type plasminogen activator is a major determinant of the basal level of activated ERK/MAP kinase and prevents apoptosis in MDA-MB-231 breast cancer cells J Cell Sci 2001, 114(Pt 18):3387-3396 11591826
6. Merchan JR Chan B Kale S Schnipper LE Sukhatme VP In vitro and in vivo induction of antiangiogenic activity by plasminogen activators and captopril J Natl Cancer Inst 2003, 95(5):388-399 12618504
7. Chappuis PO Dieterich B Sciretta V Lohse C Bonnefoi H Remadi S Sappino AP Functional evaluation of plasmin formation in primary breast cancer J Clin Oncol 2001, 19(10):2731-2738 11352966
8. Merchan JR Tang J Hu G Lin Y Mutter W Tong C Karumanchi SA Russell SJ Sukhatme VP Protease activity of urokinase and tumor progression in a syngeneic mammary cancer model J Natl Cancer Inst 2006, 98(11):756-764 16757700
9. Blasi F Proteolysis, cell adhesion, chemotaxis, and invasiveness are regulated by the u-PA-u-PAR-PAI-1 system Thromb Haemost 1999, 82(2):298-304 10605717
10. Bajou K Noel A Gerard RD Masson V Brunner N Holst-Hansen C Skobe M Fusenig NE Carmeliet P Collen D et al. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization Nat Med 1998, 4(8):923-928 10.1038/nm0898-923 9701244
11. Bajou K Masson V Gerard RD Schmitt PM Albert V Praus M Lund LR Frandsen TL Brunner N Dano K et al. The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin. Implications for antiangiogenic strategies J Cell Biol 2001, 152(4):777-784 2195770 11266468 10.1083/jcb.152.4.777
12. Ballabh P Xu H Hu F Braun A Smith K Rivera A Lou N Ungvari Z Goldman SA Csiszar A et al. Angiogenic inhibition reduces germinal matrix hemorrhage Nat Med 2007, 13(4):477-485 10.1038/nm1558 17401377
13. Chuang YH Chuang WL Huang SP Huang CH Cyclooxygenase-2 inhibitor ameliorates ureteric damage in rats with obstructed uropathy Eur J Pharmacol 2007, 569(1-2):126-137 10.1016/j.ejphar.2007.04.046 17543298
14. Lanza-Jacoby S Miller S Flynn J Gallatig K Daskalakis C Masferrer JL Zweifel BS Sembhi H Russo IH The cyclooxygenase-2 inhibitor, celecoxib, prevents the development of mammary tumors in Her-2/neu mice Cancer Epidemiol Biomarkers Prev 2003, 12(12):1486-1491 14693742
15. Basu GD Pathangey LB Tinder TL Lagioia M Gendler SJ Mukherjee P Cyclooxygenase-2 inhibitor induces apoptosis in breast cancer cells in an in vivo model of spontaneous metastatic breast cancer Mol Cancer Res 2004, 2(11):632-642 15561779
16. Sauter ER Qin W Schlatter L Hewett JE Flynn JT Celecoxib decreases prostaglandin E2 concentrations in nipple aspirate fluid from high risk postmenopausal women and women with breast cancer BMC Cancer 2006, 6:248 1621075 17049084 10.1186/1471-2407-6-248
17. Andrews HN Habibi G Kucab JE Dunn SE Celecoxib inhibits urokinase-type plasminogen activator (uPA) production in MDA-MB-231 breast cancer cells Breast cancer research and treatment 2005, 94(1):47-52 10.1007/ s10549-005-6941-5
18. Sauter ER Qin W Hewett JE Ruhlen RL Flynn JT Rottinghaus G Chen YC Celecoxib concentration predicts decrease in prostaglandin E2 concentrations in nipple aspirate fluid from high risk women BMC cancer 2008, 8:49 2259321 18267025 10.1186/1471-2407-8-49
19. Sauter ER Daly M Linahan K Ehya H Engstrom PF Bonney G Ross EA Yu H Diamandis E Prostate-specific antigen levels in nipple aspirate fluid correlate with breast cancer risk Cancer Epidemiol Biomarkers Prev 1996, 5(12):967-970 8959318
20. Sauter ER Ross E Daly M Klein-Szanto A Engstrom PF Sorling A Malick J Ehya H Nipple aspirate fluid: A promising non-invasive method to identify cellular markers of breast cancer risk Br J Cancer 1997, 76(4):494-501 9275027
21. Schonberger F Heinkele G Murdter TE Brenner S Klotz U Hofmann U Simple and sensitive method for the determination of celecoxib in human serum by high-performance liquid chromatography with fluorescence detection J Chromatogr B Analyt Technol Biomed Life Sci 2002, 768(2):255-260 10.1016/ S1570-0232(01)00588-8 11888053
22. Qin W Zhu W Wagner-Mann C Folk W Sauter ER Association of uPA, PAT-1, and uPAR in nipple aspirate fluid (NAF) with breast cancer Cancer journal (Sudbury, Mass) 2003, 9(4):293-301 10.1097/ 00130404-200307000-00012 12967140
23. Ploplis VA Tipton H Menchen H Castellino FJ A urokinase-type plasminogen activator deficiency diminishes the frequency of intestinal adenomas in ApcMin/+ mice The Journal of pathology 2007, 213(3):266-274 10.1002/ path.2236 17893885
24. Duffy MJ Reilly D McDermott E O'Higgins N Fennelly JJ Andreasen PA Urokinase plasminogen activator as a prognostic marker in different subgroups of patients with breast cancer Cancer 1994, 74(8):2276-2280 10.1002/ 1097-0142(19941015)74:8<2276::AID-CNCR2820740811>3.0.CO;2-7 7922979